AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KYMR

Booth Bruce sold $1.1M of KYMR

Booth Bruce sold 11,741 shares of Kymera Therapeutics, Inc. (KYMR) at $89.98 ($1.06M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Booth Bruce
Published Jun 23, 2026, 1:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Neutral
medium confidence
Mentioned
$KYMR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 11,741 shares at $89.98/share on 2026-06-17, with holdings after the trade reported as 0 shares.

02

Market read

Traders may monitor KYMR for follow-on insider activity, but the filing alone does not change fundamentals.

03

What to watch

The filing does not reveal reasons for the sale, and the director’s role (and any other holdings) beyond this direct position is not provided.

Relevance 5/10Novelty 5/10Timing: Form 4 filed 2026-06-22 for a 2026-06-17 sale

Background

This is an SEC Form 4 insider transaction for Kymera Therapeutics, Inc. (KYMR).

Company-level read

Ticker impact

$KYMRNeutralMedium confidence
Context

Kymera Therapeutics director Booth Bruce sold 11,741 shares in an open-market transaction for about $1.06M, leaving 0 shares.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than based on new company fundamentals.

Evidence & confidence

The filing is a routine Form 4 with a pre-arranged 10b5-1 plan and the director ends with 0 shares, but no new operational/financial information is disclosed.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide signal.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider sale by a director.

  • insider
    Booth Bruce

    Director who sold 11,741 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com